Alignment Healthcare (NASDAQ:ALHC) CEO Sells $3,274,200.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 180,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $18.19, for a total transaction of $3,274,200.00. Following the sale, the chief executive officer directly owned 2,472,641 shares of the company’s stock, valued at approximately $44,977,339.79. This represents a 6.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Alignment Healthcare Stock Down 4.9%

ALHC opened at $17.12 on Friday. The firm’s 50 day simple moving average is $20.82 and its two-hundred day simple moving average is $18.72. The company has a market capitalization of $3.50 billion, a PE ratio of -1,710.29, a PEG ratio of 2.63 and a beta of 1.18. Alignment Healthcare, Inc. has a 1-year low of $11.63 and a 1-year high of $23.87. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The company’s revenue for the quarter was up 44.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.16) EPS. As a group, equities analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Hedge Funds Weigh In On Alignment Healthcare

Large investors have recently made changes to their positions in the business. Allworth Financial LP boosted its stake in shares of Alignment Healthcare by 8.9% in the fourth quarter. Allworth Financial LP now owns 6,917 shares of the company’s stock worth $137,000 after acquiring an additional 566 shares during the period. State of Alaska Department of Revenue raised its stake in Alignment Healthcare by 6.0% during the 4th quarter. State of Alaska Department of Revenue now owns 11,296 shares of the company’s stock valued at $223,000 after purchasing an additional 636 shares during the period. Integrated Wealth Concepts LLC lifted its holdings in Alignment Healthcare by 6.3% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock worth $196,000 after purchasing an additional 665 shares in the last quarter. Parallel Advisors LLC lifted its holdings in Alignment Healthcare by 87.7% in the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock worth $33,000 after purchasing an additional 773 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Alignment Healthcare by 2.3% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,752 shares of the company’s stock worth $659,000 after purchasing an additional 844 shares during the period. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ALHC has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their price target on Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. KeyCorp reaffirmed an “overweight” rating and set a $28.00 price objective on shares of Alignment Healthcare in a research report on Thursday, January 22nd. TD Cowen boosted their price objective on Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Piper Sandler increased their target price on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Finally, UBS Group raised their target price on shares of Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alignment Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $24.56.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.